Total trials
222
Active
67
Phase 3
4
Total enrollment
64,155
Pipeline matrix
Showing 40 of 56 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Acetaminophen | — | — | — | — | — | 2 | |
| Tacrolimus | — | — | — | — | — | 2 | |
| Ibuprofen | — | — | — | — | — | 1 | |
| Everolimus | — | — | — | — | — | 1 | |
| Myfortic | — | — | — | — | — | 1 | |
| CellCept | — | — | — | — | — | 1 | |
| Imuran | — | — | — | — | — | 1 | |
| subcutaneous heparin anticoagulation | — | — | — | — | — | 1 | |
| Finerenone | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 | |
| Lotensin | — | — | — | — | — | 1 | |
| Capoten | — | — | — | — | — | 1 | |
| Enalapril | — | — | — | — | — | 1 | |
| Monopril | — | — | — | — | — | 1 | |
| Lisinopril | — | — | — | — | — | 1 | |
| Univasc | — | — | — | — | — | 1 | |
| Aceon | — | — | — | — | — | 1 | |
| Accupril | — | — | — | — | — | 1 | |
| Altace | — | — | — | — | — | 1 | |
| Mavik | — | — | — | — | — | 1 | |
| Edarbi | — | — | — | — | — | 1 | |
| Atacand | — | — | — | — | — | 1 | |
| Avapro | — | — | — | — | — | 1 | |
| Cozaar | — | — | — | — | — | 1 | |
| Benicar | — | — | — | — | — | 1 | |
| Micardis | — | — | — | — | — | 1 | |
| Diovan | — | — | — | — | — | 1 | |
| Invokana | — | — | — | — | — | 1 | |
| Farxiga | — | — | — | — | — | 1 | |
| Jardiance | — | — | — | — | — | 1 | |
| Ertugliflozin | — | — | — | — | — | 1 | |
| Brenzavvy | — | — | — | — | — | 1 | |
| Sotagliflozin | — | — | — | — | — | 1 | |
| Norco 5Mg-325Mg | — | — | — | — | — | 1 | |
| Suzetrigine | — | — | — | — | — | 1 | |
| Gabapentin | — | — | — | — | — | 1 | |
| Bupivacaine | — | — | — | — | — | 1 | |
| Skin Substitute | — | — | — | — | — | 1 | |
| Secondary Intention Healing | — | — | — | — | — | 1 | |
| Bupivacaine Hydrochloride | — | — | — | — | — | 1 |
16 more active programs hidden
Next readouts
- 2020-08-31
- 2024-12-31
- 2025-02-12
- 2025-08-01
- 2026-06
- 2026-06
- 2026-06
- 2026-11
- 2026-12-30
- 2026-12-31
Top conditions
- Spinal Cord Injuries8
- Stroke7
- Heart Failure6
- Breast Cancer5
- Aortic Stenosis4
- Obesity4
- Cardiovascular Diseases4
- Traumatic Brain Injury4
Frequently asked questions about Baylor Research Institute
- How many clinical trials does Baylor Research Institute have on ClinicalTrials.gov?
- Baylor Research Institute is listed as the lead sponsor on 222 clinical trials in ClinicalTrials.gov, 67 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Baylor Research Institute's trials are in Phase 3?
- 4 of Baylor Research Institute's trials are in Phase 3, spread across 56 active drug programs.
- What therapeutic areas does Baylor Research Institute focus on?
- Baylor Research Institute's most-studied conditions on ClinicalTrials.gov are Spinal Cord Injuries, Stroke, Heart Failure, Breast Cancer, Aortic Stenosis.
- When are Baylor Research Institute's next clinical trial readouts?
- Baylor Research Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “Alirocumab in Patients on a Stable Dialysis Regimen”, expected around 2020-08-31.